BDR Pharmaceuticals Sues FDA Over VOQUEZNA Exclusivity

The drugmaker challenges federal regulations to allow generic competition for the gastrointestinal treatment.

Updated on Oct. 23, 2026 in Healthcare

BDR Pharmaceuticals Sues FDA Over VOQUEZNA Exclusivity

Live Poll

Should federal regulators prioritize extending drug exclusivity periods to reward innovation over promoting generic competition?

BDR Pharmaceuticals International Pvt. Ltd. has filed a lawsuit against the FDA in the U.S. District Court for the District of Columbia. The litigation challenges the FDA's decision to maintain exclusivity for Phathom Pharmaceuticals' drug VOQUEZNA until May 2032.

Why it matters

The suit aims to overturn current FDA policy to permit earlier generic drug acceptance, which could significantly impact the market timeline for competitive treatments. Phathom Pharmaceuticals currently relies on VOQUEZNA exclusivity, which is projected to last more than six years without competition.

Phathom Pharmaceuticals reported $175.1 million in net revenue for 2025, a 217% increase over the $55.3 million reported in 2024. Shares of the company fell 23% on October 23, 2026, contributing to a 67% year-to-date decline in stock price.

The players

BDR Pharmaceuticals International Pvt. Ltd.

This pharmaceutical company is challenging current federal drug exclusivity standards.

FDA

The federal agency is responsible for regulating drug approvals and maintaining exclusivity periods for medications.

Phathom Pharmaceuticals

This company markets the gastrointestinal drug VOQUEZNA and is experiencing significant stock price volatility.

The details

BDR Pharmaceuticals claims the FDA improperly applied laws to grant extended market protection to the medication. The company has submitted an abbreviated new drug application for a generic version of the treatment, which the agency previously refused to accept.

VOQUEZNA was first approved in May 2022.
Phathom Pharmaceuticals reported $175.1 million in net revenue for full-year 2025.
Phathom shares fell roughly 23 percent on October 23, 2026.
VOQUEZNA exclusivity and generic protection ends in May 2032.

Market Landscape

This lawsuit challenges the application of the Hatch-Waxman Act's drug exclusivity provisions, which dictate when manufacturers can bring generic competitors to market. It represents a significant attempt by a generic drugmaker to disrupt the current period of market protection for a branded medication.

Shareholders of Phathom Pharmaceuticals face volatility as the court case proceeds through the federal legal system. Patients waiting for potentially lower-cost generic versions of the medication will have to wait for the resolution of this exclusivity dispute.

The takeaway

Legal challenges to FDA exclusivity periods can lead to sudden shifts in company valuations and long-term product pricing. Investors should monitor court filings in the District of Columbia for potential changes to the competitive timeline for specialized drugs.